ANGLE plc provided earnings guidance for the year 2023. The Company expects revenue recognised for 2023 will be c. £2.2 million, which is an increase of 120% over revenue achieved in 2022 but below current market consensus of c. £3.0 million. New sales secured in 2023 are expected to be c. £3.3 million however revenue recognition for some of these sales will fall into the 2024 financial year.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
20.5 GBX | -2.38% | -3.53% | +74.47% |
05-03 | Angle shares up on assay development deal with AstraZeneca | AN |
05-03 | Angle shares up on assay development deal with AstraZenaca | AN |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+74.47% | 68.66M | |
-13.15% | 18.53B | |
-41.44% | 2.82B | |
+20.51% | 1.91B | |
-1.13% | 1.65B | |
+26.70% | 1.25B | |
-14.07% | 988M | |
-20.60% | 910M | |
+2.50% | 786M | |
-23.66% | 634M |
- Stock Market
- Equities
- AGL Stock
- News ANGLE plc
- ANGLE plc Provides Earnings Guidance for the Year 2023